Bradykinnins - Receptor Antagonists

Product #

Image

Product Name

Biochem/physiol Actions

Gene Symbol (ID)

Add to Cart

B3811   B-9430 trifluoroacetate salt ≥98% (HPLC) B-9430 was developed by Gera at the Stewart laboratory1 and is a stable, potent, and long lasting Bradykinin (BK) antagonist, a candidate anti-inflammatory drug. B-9430 shows potency at bradykinin B2 (pA2 = 8.6) and B1 receptors (pA2 = 7.3). Bradykinin is an important growth factor for small-cell lung cancer (SCLC) and prostate cancer (PC). BK receptors are expressed on almost all lung cancer cell lines and on many PC cells. B-9430 is very resistant to kinases and thus shows a very long action in vivo. This peptide is unique among bradykinin antagonists in that it is active after oral administration.
 
B1542 [Lys-des-Arg9]-Bradykinin ≥95% (HPLC) [Des-Arg10]-kallidin is a bradykinin B1 receptor agonist. It strongly upregulates the B1 receptor and is blocked by a specific protein kinase C inhibitor. The upregulation is correlated with the induction of transcription factor nuclear factor κB (NF-κB).
human ... KNG1 (includes EG:3827)(3827)
B6929 Lys-(des-Arg9, Leu8)-Bradykinin trifluoroacetate salt ≥95% B1 bradykinin receptor antagonist.
human ... BDKRB1(623)
mouse ... BDKRB1(12061)
rat ... BDKRB1(81509)
H157 HOE 140 ≥94% B2 bradykinin receptors are present in the sensory neurons. Activation of B2 receptor by bradykinin is associated with pro-inflammatory, pain producing and cardiovascular responses. HOE-140 is a selective B2 bradykinin receptor antagonist. Presence of HOE-140 suppresses the effects of bradykinin and has been shown to have anti-hyperalgesic response, particularly towards inflammatory pain.
human ... BDKRB2(624)
mouse ... BDKRB2(12062)
rat ... BDKRB2(25245)